DTS-108

a peptidic prodrug of SN38/irinotecan, developed to bypass hepatic activation and reduce the gastrointestinal toxicity and interpatient variability compared with irinotecan; structure in first source

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bouattour, Mohammed: 1 article (01/2016)
2.	Coriat, Romain: 1 article (01/2016)
3.	Desjardins, Robert: 1 article (01/2016)
4.	Dreyer, Chantal: 1 article (01/2016)
5.	Faivre, Sandrine J: 1 article (01/2016)
6.	Goldwasser, François: 1 article (01/2016)
7.	Mir, Olivier: 1 article (01/2016)
8.	Raymond, Eric: 1 article (01/2016)
9.	Ropert, Stanislas: 1 article (01/2016)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2016 - "The RP2D for intravenous DTS-108 was 313 mg/m2 every 2 weeks in patients with advanced/metastatic solid tumors." 01/01/2016 - "Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study."
2.	Carcinoma (Carcinomatosis) 01/01/2016 - "The pharmacokinetics of DTS-108, adverse events graded according to NCI-CTCv3.1, dose-limiting toxicities at cycle 1, the maximum tolerated dose (MTD), and the recommended Phase II dose (RP2D) of intravenous DTS-108 (1-2 hours) every 2 weeks were evaluated in a first-in-human Phase I study in patients with advanced/metastatic carcinomas, according to an accelerated dose escalation design. "

Related Drugs and Biologics

1.	Oligopeptides
2.	Esterases
3.	Irinotecan (Camptosar)